Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The new bispecific antibody class (bsAbs) has emerged as one of the fastest-growing next-generation antibody therapies, due to its high specificity and low toxicity. bsAbs are designed to have two specific antigen-binding sites, unlike conventional antibody formats. Rapid and accurate functional evaluation methods and stability characterization are required to ensure product quality, safety, and efficacy.
In this study, we evaluated the stability of a bispecific mouse antibody targeting CD200 and CD47 in mouse, proteins over-expressed in many cancers, under heat stress conditions: